Tumor necrosis factor antagonists in the therapy of psoriasis

Clinics in Dermatology

Volumn 26, Issue 5, 2008, Pages 486-502

  Mössner, Rotraut ^a   Schön, Michael P ^b,c,d   Reich, Kristian ^a,e  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b Deutsche Forschungsgemeinschaft   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^e DERMATOLOGIKUM HAMBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CYCLOSPORIN A; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PLACEBO;

ALLERGY; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; APLASTIC ANEMIA; ARTICLE; BLOOD DYSCRASIA; BLOOD TOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DEMYELINATING DISEASE; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG SPECIFICITY; FEVER; FIBROSING ALVEOLITIS; FLUSHING; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEART FAILURE; HEPATITIS; HUMAN; INFECTION; INJECTION SITE REACTION; INTERSTITIAL PNEUMONIA; LUPUS ERYTHEMATOSUS; MAXIMUM PLASMA CONCENTRATION; MENORRHAGIA; MONOTHERAPY; NONHUMAN; OPPORTUNISTIC INFECTION; PANCREATITIS; PRIORITY JOURNAL; PRURITUS; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SIDE EFFECT; SYMPTOMATOLOGY; T CELL LYMPHOMA; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUBERCULOSIS; URTICARIA; VASCULITIS;

ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOGLOBULIN G; PSORIASIS; QUALITY OF LIFE; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 47949102423     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2007.10.030     Document Type: Article

References (81)

1. Nickoloff B.J. The cytokine network in psoriasis. Arch Dermatol 127 (1991) 871-884
2. Nickoloff B.J., Xin H., Nestle F.O., and Qin J.Z. The cytokine and chemokine network in psoriasis. Clin Dermatol (2007)
3. Schön M.P., and Boehncke W.H. Psoriasis. N Engl J Med 352 (2005) 1899-1912
4. Mössner R., Kingo K., Kleensang A., et al. Association of TNF-238 and -308 promoter polymorphisms with psoriasis vulgaris and psoriatic arthritis but not with pustulosis palmoplantaris. J Invest Dermatol 124 (2005) 282-284
5. Schön M.P. Advances in psoriasis treatment. Lancet 366 (2005) 1333-1335
6. Scallon B.J., Moore M.A., Trinh H., Knight D.M., and Ghrayeb J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 7 (1995) 251-259
7. Van den Brande J.M., Braat H., van den Brink G.R., et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 124 (2003) 1774-1785
8. Di Sabatino A., Ciccocioppo R., Cinque B., et al. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease. Gut 53 (2004) 70-77
9. Reich K., Nestle F.O., Papp K., et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 366 (2005) 1367-1374
10. Chaudhari U., Romano P., Mulcahy L.D., et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 357 (2001) 1842-1847
11. Gottlieb A.B., Evans R., Li S., et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 51 (2004) 534-542
12. Furst D.E., Wallis R., Broder M., and Beenhouwer D.O. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum 36 (2006) 159-167
13. Nestorov I., Zitnik R., DeVries T., et al. Pharmacokinetics of subcutaneously administered etanercept in subjects with psoriasis. Br J Clin Pharmacol 62 (2006) 435-445
14. Gottlieb A.B., Matheson R.T., Lowe N., et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 139 (2003) 1627-1632
15. Leonardi C.L., Powers J.L., Matheson R.T., et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 349 (2003) 2014-2022
16. Papp K.A., Tyring S., Lahfa M., et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 152 (2005) 1304-1312
17. Gordon K.B., Langley R.G., Leonardi C., et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 55 (2006) 598-606
18. Nestorov I. Clinical pharmacokinetics of TNF antagonists: how do they differ?. Semin Arthritis Rheum 34 (2005) 12-18
19. Humira 40mg prescribing information (Fachinformation). Abbot Laboratories, Kent, United Kingdom. June 2006.
20. Mease P.J., Gladman D.D., Ritchlin C.T., et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52 (2005) 3279-3289
21. Reich K., Nestle F.O., Papp K., et al. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. Br J Dermatol 154 (2006) 1161-1168
22. Shikiar R., Willian M.K., Okun M.M., Thompson C.S., and Revicki D.A. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health Qual Life Outcomes 4 (2006) 71
23. Gladman D.D., Mease P.J., Cifaldi M.A., et al. Adalimumab improves joint- and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 66 (2007) 163-168
24. http://www.jnj.com/news/jnj_news/20070202_161407.htm. Accessed 13.01.2007.
25. http://www.medicalnewstoday.com/medicalnews.php?Fnewsid-53536. Accessed 13.01.2007.
26. http://www.medicalnewstoday.com/medicalnews.php?Fnewsid-55648. Accessed 13.01.2007.
27. Hetland M.L., Unkerskov J., Ravn T., et al. Routine database registration of biological therapy increases the reporting of adverse events twentyfold in clinical practice. First results from the Danish Database (DANBIO). Scand J Rheumatol 34 (2005) 40-44
28. Baert F., Noman M., Vermeire S., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348 (2003) 601-608
29. Cheifetz A., and Mayer L. Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt Sinai J Med 72 (2005) 250-256
30. Cheifetz A., Smedley M., Martin S., et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 98 (2003) 1315-1324
31. Infliximab. Remicade 100mg prescribing information (Fachinformation). Centocor, Leiden, the Netherlands. September 2006. Remicade 2006.
32. Lelong J., Duburque C., Fournier C., et al. [Desensitisation to infliximab in patients with Crohn's disease]. Rev Mal Respir 22 (2005) 239-246
33. Enbrel 25mg prescribing information (Fachinformation) (2006), Wyeth, Berkshire (United Kingdom)
34. Zeltser R., Valle L., Tanck C., et al. Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion protein. Arch Dermatol 137 (2001) 893-899
35. Bongartz T., Sutton A.J., Sweeting M.J., et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295 (2006) 2275-2285
36. Dixon W.G., Watson K., Lunt M., et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 54 (2006) 2368-2376
37. Tubach F., Ravaud P., Salmon-Ceron D., et al. Emergence of Legionella pneumophila pneumonia in patients receiving tumor necrosis factor-alpha antagonists. Clin Infect Dis 43 (2006) e95-e100
38. Rychly D.J., and DiPiro J.T. Infections associated with tumor necrosis factor-alpha antagonists. Pharmacotherapy 25 (2005) 1181-1192
39. Wallis R.S., Broder M., Wong J., Lee A., and Hoq L. Reactivation of latent granulomatous infections by infliximab. Clin Infect Dis 41 Suppl 3 (2005) S194-S198
40. Winthrop K.L. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol 2 (2006) 602-610
41. Atzeni F., Sarzi-Puttini P., Dell' Acqua D., et al. Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. Arthritis Res Ther 8 (2005) R3
42. De Rycke L., Baeten D., Kruithof E., et al. The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications. Lupus 14 (2005) 931-937
43. De Bandt M., Sibilia J., Le L.X., et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 7 (2005) R545-R551
44. Misery L., Perrot J.L., Gentil-Perret A., et al. Dermatological complications of etanercept therapy for rheumatoid arthritis. Br J Dermatol 146 (2002) 334-335
45. Phelan C., and Wooltorton E. Infliximab and serious hematologic events. CMAJ 171 (2004) 1045
46. Montane E., Salles M., Barriocanal A., et al. Antitumor necrosis factor-induced neutropenia: a case report with double positive rechallenges. Clin Rheumatol 26 (2007) 1527-1529
47. Smedby K.E., Hjalgrim H., Askling J., et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst 98 (2006) 51-60
48. Baecklund E., Iliadou A., Askling J., et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 54 (2006) 692-701
49. Marcil I., and Stern R.S. Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. Lancet 358 (2001) 1042-1045
50. Paul C.F., Ho V.C., McGeown C., et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol 120 (2003) 211-216
51. Askling J., Fored C.M., Brandt L., et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 64 (2005) 1421-1426
52. Tuberculosis associated with blocking agents against tumor necrosis factor-alpha-California, 2002-2003. MMWR Morb Mortal Wkly Rep 53 (2004) 683-686
53. Mazurek G.H., Jereb J., Lobue P., et al. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 54 (2005) 49-55
54. Zein N.N. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 42 (2005) 315-322
55. Millonig G., Kern M., Ludwiczek O., Nachbaur K., and Vogel W. Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening?. World J Gastroenterol 12 (2006) 974-976
56. Felson D.T., Anderson J.J., Boers M., et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38 (1995) 727-735
57. Antoni C.E., Kavanaugh A., Kirkham B., et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Arthritis Rheum 52 (2005) 1227-1236
58. Antoni C., Krueger G.G., de Vlam K., et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 64 (2005) 1150-1157
59. Mease P.J., Kivitz A.J., Burch F.X., et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 50 (2004) 2264-2272
60. Mease P.J., Goffe B.S., Metz J., et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356 (2000) 385-390
61. Kavanaugh A., Antoni C.E., Gladman D.D., et al. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis 65 (2006) 1038-1043
62. Mease P.J., Kivitz A.J., Burch F.X., et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol 33 (2006) 712-721
63. Hawrot A.C., Metry D.W., Theos A.J., and Levy M.L. Etanercept for psoriasis in the pediatric population: experience in nine patients. Pediatr Dermatol 23 (2006) 67-71
64. Papoutsaki M., Costanzo A., Massotta A., et al. Etanercept for the treatment of severe childhood psoriasis. Br J Dermatol 154 (2006) 181-183
65. Kress D.W. Etanercept therapy improves symptoms and allows tapering of other medications in children and adolescents with moderate to severe psoriasis. J Am Acad Dermatol 54 (2006) S126-S128
66. Farnsworth N.N., George S.J., and Hsu S. Successful use of infliximab following a failed course of etanercept in a pediatric patient. Dermatol Online J 11 (2005) 11
67. Menter M.A., and Cush J.M. Successful treatment of pediatric psoriasis with infliximab. Pediatr Dermatol 21 (2004) 87-88
68. Esposito M., Mazzotta A., de Felice C., Papoutsaki M., and Chimenti S. Treatment of erythrodermic psoriasis with etanercept. Br J Dermatol 155 (2006) 156-159
69. Heikkila H., Ranki A., Cajanus S., and Karvonen S.L. Infliximab combined with methotrexate as long-term treatment for erythrodermic psoriasis. Arch Dermatol 141 (2005) 1607-1610
70. Schmick K., and Grabbe J. Recalcitrant, generalized pustular psoriasis: rapid and lasting therapeutic response to antitumour necrosis factor-alpha antibody (infliximab). Br J Dermatol 150 (2004) 367
71. Kamarashev J., Lor P., Forster A., et al. Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept. Dermatology 205 (2002) 213-216
72. Trent J.T., and Kerdel F.A. Successful treatment of Von Zumbusch pustular psoriasis with infliximab. J Cutan Med Surg 8 (2004) 224-228
73. Benoit S., Toksoy A., Bröcker E.B., Gillitzer R., and Goebeler M. Treatment of recalcitrant pustular psoriasis with infliximab: effective reduction of chemokine expression. Br J Dermatol 150 (2004) 1009-1012
74. Callen J.P., and Jackson J.H. Adalimumab effectively controlled recalcitrant generalized pustular psoriasis in an adolescent. J Dermatolog Treat 16 (2005) 350-352
75. Rich S.J. Considerations for assessing the cost of biologic agents in the treatment of psoriasis. J Manag Care Pharm 10 (2004) S38-S41
76. Sohn S., Schoeffski O., Prinz J., et al. Cost of moderate to severe plaque psoriasis in Germany: a multicenter cost-of-illness study. Dermatology 212 (2006) 137-144
77. Miller D.W., and Feldman S.R. Cost-effectiveness of moderate-to-severe psoriasis treatment. Expert Opin Pharmacother 7 (2006) 157-167
78. Heydendael V.M., Spuls P.I., Opmeer B.C., et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 349 (2003) 658-665
79. Jacobsson L.T., Turesson C., Gulfe A., et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 32 (2005) 1213-1218
80. Mössner R., and Reich K. Infliximab in the treatment of psoriasis. Expert Rev Dermatol 1 (2006) 515-526
81. Reich K., and Augustin M. Biologics in the treatment of psoriasis. Arzneimitteltherapie 23 (2005) 384-397